Funds to better understand Friedreich ataxia drug
Posted: 27 November 2024 Associate Professor Shiang (Max) Lim, of SVI’s O’Brien Department, has been awarded funding from the Friedreich’s Ataxia Research Alliance (FARA) to better understand the effect of omaveloxolone – a recently FDA-approved drug – on…
St Vincent’s Allied Health Excellence Awards highlight patient care, innovation and leadership
Posted: 27 November 2024 St Vincent’s Hospital Melbourne has honoured its 2024 Allied Health Excellence Awards winners, recognising the pivotal role allied health professionals play in delivering high-quality, multidisciplinary care. With over 60 nominations from more than 500 allied health employees, the awards highlighted the…
Enabling circular economy practices in sustainable metal production
Posted: 27 November 2024 Researchers in the DIAMETER project will develop digital platforms focused on augmented sustainability and circularity of additive manufacturing and machining processes. A new four-year project has been awarded €6 million (AUD$9.7 million) by the…
Insights from BioForum’s fireside chat with Marissa Senzaki, featuring Ashwin Ramanchandra: How smart talent strategies drive the success of sustainable ventures
Posted: 27 November 2024 Talent. It’s often said to be the single biggest asset of any company, yet for startups – especially in the healthtech and biotech sectors – attracting, retaining and empowering the right people is one…
New hope for diabetic heart disease treatment
Posted: 27 November 2024 Monash University drug discovery researchers have found that a natural fat molecule called ‘lipoxin A4’ (LXA4) could significantly reduce inflammation and improve function for diabetic hearts. The preclinical study, published in Cardiovascular Diabetology, found LXA4, which…
Monash-led research is expanding treatment options for high cholesterol
Posted: 27 November 2024 Melbourne researchers are helping expand options for people with high cholesterol that puts them at risk of heart attack or stroke, including world-first drugs for potentially deadly conditions. Monash University and Monash Health are…
$29.9 million in Linkage Projects to support research partnerships
Posted: 27 November 2024 The Australian Research Council (ARC) today announced $29.9 million in funding for 56 new projects under the ARC’s Linkage Project scheme 2024 Round 1. ARC Acting Chief Executive Officer, Dr Richard Johnson, said the…
Medicines Australia welcomes announcement of HTA Implementation Advisory Group and two industry representatives
Posted: 27 November 2024 Medicines Australia welcomes the announcement of the independent HTA Reform Implementation Advisory Group and the appointment of CEO Liz de Somer and Board Deputy Chair Anne Harris as industry’s representatives. “The independent Implementation Advisory…
BioMelbourne Network Annual General Meeting 2024: reflections, change and opportunities
Posted: 22 November 2024 BioMelbourne Network’s 2024 Annual General Meeting (AGM) brought together over 100 members in Melbourne. The event provided an opportunity to reflect on the highlights of FY24, explore the organisation’s new opportunities for advancing the…
SUCCESSFUL COMPLETION OF PLANNED IDMC REVIEW OF ACTION3 PHASE 3 FSGS KIDNEY TRIAL
Posted: 20 November 2024 Dimerix Limited (ASX: DXB) a biopharmaceutical company with late-stage clinical assets in inflammatory diseases, today confirmed that the Independent Data Monitoring Committee (IDMC) successfully concluded a fifth review of the ACTION3 phase 3 clinical…
ViiV HEALTHCARE ANNOUNCES DATA DEMONSTRATING DOVATO (DTG/3TC) IS HIGHLY EFFECTIVE IN TREATMENT-NAIVE PEOPLE WITH ADVANCED HIV
Posted: 20 November 2024 ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced 48-week findings from the DOLCE study, sponsored by Fundación Huésped and the Bahiana Foundation of…
Psilocybin shows promise for treating obsessive compulsive disorder
Posted: 20 November 2024 A single dose may reduce compulsive behaviours in mice Research at The Florey suggests the psychedelic compound psilocybin has potential to treat obsessive-compulsive disorder (OCD) and related disorders. The study – led by Florey…
